A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Completed · Phase 1

Conditions studied: Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma, Advanced Malignancies Except Leukemia

In brief

PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.

Key facts

Study ID

NCT00585195

Run by

Pfizer

People needed

596

Starts

2006-04-19

Expected to finish

2022-01-19

Last updated by the study team

2023-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced malignancies (except leukemias), histologically proven at diagnosis; Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS
• Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients with non-measurable disease may enter on a case-by-case basis); not required for DDI sub-studies.
• Adequate blood cell counts, kidney function, liver function and Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG score of 2 may be allowed on a case-by-case basis)

You may not qualify if…

• Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of starting study treatment, depending on the patient cohort
• Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma
• Active or unstable cardiac disease or heart attack within 3 months of starting study treatment

Where it is running

• University of California, Irvine Medical Center — Orange, California, United States
• University of Colorado Hospital/ Anschutz Cancer Pavilion — Aurora, Colorado, United States
• University of Colorado Hospital — Aurora, Colorado, United States
• University of Colorado — Aurora, Colorado, United States
• University of Chicago — Chicago, Illinois, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Ophthalmic Consultants of Boston Inc. — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana Farber Cancer Center — Boston, Massachusetts, United States
• Joslin Beetham Eye Institute — Boston, Massachusetts, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Kresge Eye Institute — Detroit, Michigan, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Memorial Sloan Kettering Cancer Center: Breast and Imaging Center — New York, New York, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• UNC Hospitals — Chapel Hill, North Carolina, United States
• The James Cancer Hospital and Solove Research Institute — Columbus, Ohio, United States
• Ohio State Eye and Ear Institute — Columbus, Ohio, United States
• The Ohio State University Martha Morehouse Medical Plaza — Columbus, Ohio, United States
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States
• Henry-Joyce Cancer Clinic — Nashville, Tennessee, United States
• Vanderbilt Eye Institute — Nashville, Tennessee, United States
• The University of Vermont Medical Center — Burlington, Vermont, United States
• The University of Vermont Cancer Center — Burlington, Vermont, United States
• Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.